Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

8.15USD
15 Dec 2017
Change (% chg)

$-0.10 (-1.21%)
Prev Close
$8.25
Open
$8.24
Day's High
$8.39
Day's Low
$7.99
Volume
776,140
Avg. Vol
521,528
52-wk High
$25.11
52-wk Low
$5.91

Select another date:

Mon, Dec 11 2017

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

BRIEF-NewLink Genetics reports Q3 loss per share $0.69

* NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​

BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod

* Newlink Genetics announces FDA orphan-drug designation for Indoximod

BRIEF-NewLink Genetics announces proposed public offering of common stock

* NewLink Genetics announces proposed public offering of common stock

BRIEF-NewLink Genetics forecasts co will have about $100 million in cash and cash equivalents on balance sheet

* NewLink Genetics - forecasts that co will have about $100 million in cash and cash equivalents on its balance sheet as of December 31, 2017 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

* NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

BRIEF-NewLink Genetics announces clinical collaboration with AstraZeneca​

* Newlink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

BRIEF-NewLink Genetics Q2 loss per share $0.57

* NewLink Genetics - ‍expect to end 2017 with approximately $75 million in cash and equivalents, which excludes any cash that may be received from financing​

BRIEF-Newlink Genetics ‍receives notice of allowance from USPTO covering indoximod salts and prodrugs​

* Newlink Genetics says ‍receives notice of allowance from USPTO covering indoximod salts and prodrugs​ Source text for Eikon: Further company coverage:

Select another date: